Ratutrelvir

Ratutrelvir (0-100 μM; 24-96 h) potently reduces the viability of MCF-7 cells, with an IC₅₀ of 53.9 μM; it only exerts weak inhibitory effects on MDA-MB-231 and MCF-10A cells at high concentrations, and shows no inhibitory effect on the viability of BT474 cells^[1].
Ratutrelvir (0-100 μM; 48 h) inhibits colony formation of MCF-7 cells in a concentration-dependent manner, suppresses colony formation of MDA-MB-231 cells at a concentration of 50 μM, and exerts no effect on colony formation of BT474 cells^[1].
Ratutrelvir (25 μM; 48 h) significantly inhibits the migration of MCF-7 cells, but exerts no effect on the migration of MDA-MB-231 or BT474 cells^[1].
Ratutrelvir (12.5 μM; 72 h) significantly reduces the invasive ability of MCF-7 cells, but exerts no effect on the invasive ability of MDA-MB-231 or BT474 cells^[1].
Ratutrelvir (0-100 μM; 12 h) inhibits the NF-κB pathway in MCF-7 cells by reducing the levels of p-NF-κB p65 and p-IκBα and blocking the nuclear translocation of NF-κB p65, but exerts no effect on the NF-κB pathway in MDA-MB-231 or BT474 cells^[1].
Ratutrelvir (50 μM; 2, 4, 6, 8, 12 h) inhibits the DNA-binding activity of NF-κB in MCF-7 cells in a time-dependent manner in vitro, but exerts no effect on this activity in MDA-MB-231 or BT474 cells^[1].
Ratutrelvir (0-100 μM; 96 h) inhibits TNF-α-mediated NF-κB activation in MCF-7 cells, and TNF-α can partially reverse the inhibitory effects of Ratutrelvir on the proliferation, migration and invasion of MCF-7 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.